Pycnogenol vs Generic Pine Bark Extract: Are They the Same Thing?

By Erin Rose · Updated July 19, 2026 · Methodology

Educational overview — not medical advice. No human trial in this evidence pack has tested a generic pine bark extract head-to-head against Pycnogenol®. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

What Pycnogenol® actually is

Pycnogenol® is a specific, patented, manufacturer-controlled extract of French maritime pine bark (Pinus pinaster ssp. atlantica), standardized by its maker, Horphag Research, to roughly 65–75% procyanidins on every batch. That single-source manufacturing control is exactly what makes it the consistent, tested article across the human RCTs — researchers can specify "Pycnogenol®" in a trial protocol and know they're getting a defined, repeatable material. A "generic pine bark extract" label, by contrast, can mean almost any pine bark preparation, standardized to almost any degree (or not standardized at all), from almost any manufacturer — there's no single defined article behind that phrase the way there is behind the trademark.

How concentrated is the positive literature in Pycnogenol specifically?

Extremely. Of the 13 individual human trials and reviews in this evidence pack beyond the independent Cochrane review, essentially all test Pycnogenol by name: Liu 2004 and Cesarone 2010 are co-authored by Peter Rohdewald — the chemist who patented and developed Pycnogenol, a direct financial and intellectual conflict of interest. Steigerwalt 2009 (diabetic retinopathy) co-authors a researcher affiliated with Horphag. And most tellingly, Weichmann & Rohdewald 2024 — a narrative review summarizing "39 gold standard" Pycnogenol trials as broadly positive across nearly every marketed use — discloses in its own text: "FW was an employee of Horphag Research." That is not incidental context; it is the single clearest piece of evidence in this pack for how concentrated the positive Pycnogenol literature is in industry-affiliated hands. It's a narrative review, not a systematic review or meta-analysis — no PRISMA methodology, no pooled effect sizes, no formal bias assessment — and should never be cited as independent proof of efficacy, only as evidence of the industry-concentration problem itself.

Beyond Rohdewald and Horphag directly, a third pattern compounds the concentration problem: several of the CVI, edema, and retinopathy trials in this pack — Cesarone 2010, Belcaro 2018 (the LONFLIT registry study), and Steigerwalt 2009 — come from one small, extremely prolific Italian research group (Cesarone, Belcaro, and colleagues at the San Valentino Vascular Screening Project, Chieti/Pescara). That group's papers recur across nearly every condition Pycnogenol is marketed for. Treat their repeated appearance as a single recurring source, not as three or four independent confirmations of the same finding.

The one non-Pycnogenol trial: Drieling 2010

Drieling 2010 is the exception that proves the rule. A randomized, double-blind, placebo-controlled RCT (n=130 at-risk adults), Stanford Prevention Research Center, NIH-registered (NCT00425945) — genuinely independent, academic, non-industry. It tested a different, non-Pycnogenol pine bark extract (Flavagenol/Toyo-FVG, from manufacturer Toyo Bio-Pharma/Shinyaku) at 200mg/day for 12 weeks. PRIMARY ENDPOINT was blood pressure — NOT MET: no significant difference between groups (p=.87), and no significant effect on BMI, lipids, liver enzymes, LDL particle size, insulin, Lp(a), or hs-CRP either. The authors' conclusion: "our results are consistent with a general failure of antioxidants to demonstrate cardiovascular benefits." This trial can't be used to claim Pycnogenol itself failed — it tested a different product — but it is the clearest independent, non-industry, academic null RCT for "pine bark extract" as a category, and it directly undercuts any assumption that all pine bark extracts behave the same way.

As an Amazon Associate we earn from qualifying purchases. Full genuine-vs-generic ranking on best pine bark extract — never by commissions.

Pine bark vs grape seed: which OPC source has better evidence?

Both pine bark extract and grape seed extract are proanthocyanidin (OPC) extracts marketed for circulation and blood pressure, and both have real but modest human evidence. The honest difference is concentration: grape seed extract's three blood-pressure meta-analyses (Feringa 2011, Zhang 2016, Foshati 2022) come from more methodologically independent trial pools, without the same single-patented-ingredient dominance seen in pine bark's Pycnogenol-heavy literature. Neither ingredient has a strong, settled evidence base — see grape seed extract's own meta-analysis reckoning for the parallel honest breakdown — but pine bark's is more concentrated in one company's product and one recurring research group, which is exactly why the genuine-vs-generic distinction matters so much more here.

Frequently asked questions

Related

• Pine Bark Extract: what it is & who it's for
• Best Pine Bark Extract Supplement — genuine Pycnogenol® vs generic, ranked
• Pine Bark Extract for Blood Pressure and Circulation
• Dosage Guide
• Grape Seed Extract — the sibling OPC extract, with a more independent evidence base
• Does Grape Seed Extract Actually Lower Blood Pressure?

Sources